Abstract

We demonstrate that the antimicrobial peptide, melittin, is effective alone and in combination with the aminoglycosides tobramycin to kill Pseudomonas aeruginosa growing as biofilms both in vitro and in vivo. Melittin and tobramycin show enhanced in vitro activity in combination at micromolar concentrations, resulting in a 2-log10 reduction in the number of cells within mature PAO1 P. aeruginosa biofilms after 6-h of treatment. Alternatively, either agent alone resulted in half-a-log10 reduction. Time-killing assays demonstrated that the combination of melittin and tobramycin was effective at 2-h whereas tobramycin was not effective until after 6-h of treatment. We also found the combination was more effective than tobramycin alone against biofilms of 7 P. aeruginosa cystic fibrosis clinical isolates, resulting in a maximum 1.5-log10 cellular reduction. Additionally, melittin alone was effective at killing biofilms of 4 Staphylococcus aureus isolates, resulting in a maximum 2-log10 cellular reduction. Finally, melittin in combination with tobramycin embedded in an agarose-based hydrogel resulted in a 4-fold reduction in bioluminescent P. aeruginosa colonizing mouse wounds by 4-h. In contrast, tobramycin or melittin treatment alone did not cause a statistically significant reduction in bioluminescence. These data demonstrate that melittin in combination with tobramycin embedded in a hydrogel is a potential treatment for biofilm-associated wound infections.

Highlights

  • Biofilms represent a unique challenge in that they possess several antibacterial tolerance mechanisms, contributing to resistance and negating our antibacterial arsenal (Lewis, 2001; Brown and Wright, 2016)

  • Because gentamicin and tobramycin when combined with melittin exhibited similar enhancement of biofilm killing of P. aeruginosa PAO1, for the remainder of this work we studied the activity of the combination of tobramycin and melittin

  • For 3/4 of the S. aureus strains, the combination of tobramycin and melittin was similar to melittin alone, while a slight but significant enhancement was observed for MRSA_USA300. These results suggest that melittin and not tobramycin primarily drives killing of S. aureus biofilms

Read more

Summary

INTRODUCTION

Biofilms represent a unique challenge in that they possess several antibacterial tolerance mechanisms, contributing to resistance and negating our antibacterial arsenal (Lewis, 2001; Brown and Wright, 2016). Biofilms consist of cells imbedded in an extracellular polymeric substance made up of polysaccharides, proteins, and DNA that creates a barrier to the host immune system, slows the diffusion of antimicrobials and gives rise to slow-growing or dormant persister cells (Donlan and Costerton, 2002) These tolerance mechanisms render cells growing as biofilms up to 1,000-times more resistant to antibacterial therapies compared to planktonic cells (Lewis, 2001). We found that the combination of tobramycin with melittin showed non-additive enhanced activity in vitro to eradicate biofilms of multiple clinical isolates of P. aeruginosa. This combination was effective at killing biofilms of Staphylococcus aureus in vitro, primarily due to melittin activity. Our findings suggest that melittin in combination with tobramycin could represent a potential new therapy for the treatment of biofilm-associated infections in diabetic foot and burn wounds as applied to the surface in a hydrogel

MATERIALS AND METHODS
Ethics Statement
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call